JP2010520223A - 発作関連障害のための組成物および方法 - Google Patents

発作関連障害のための組成物および方法 Download PDF

Info

Publication number
JP2010520223A
JP2010520223A JP2009551873A JP2009551873A JP2010520223A JP 2010520223 A JP2010520223 A JP 2010520223A JP 2009551873 A JP2009551873 A JP 2009551873A JP 2009551873 A JP2009551873 A JP 2009551873A JP 2010520223 A JP2010520223 A JP 2010520223A
Authority
JP
Japan
Prior art keywords
substituted
alkyl
compound
hydrogen
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009551873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010520223A5 (de
Inventor
ディー． マーティン ワッターソン，
エルディク， リンダ ジェイ． バン
マーク エス． ウェインライト，
Original Assignee
ノースウェスタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースウェスタン ユニバーシティ filed Critical ノースウェスタン ユニバーシティ
Publication of JP2010520223A publication Critical patent/JP2010520223A/ja
Publication of JP2010520223A5 publication Critical patent/JP2010520223A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2009551873A 2007-03-02 2008-02-29 発作関連障害のための組成物および方法 Pending JP2010520223A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US90460607P 2007-03-02 2007-03-02
US438507P 2007-11-27 2007-11-27
PCT/US2008/055495 WO2008109437A2 (en) 2007-03-02 2008-02-29 Compositions and treatments for seizure-related disorders

Publications (2)

Publication Number Publication Date
JP2010520223A true JP2010520223A (ja) 2010-06-10
JP2010520223A5 JP2010520223A5 (de) 2012-03-29

Family

ID=39345468

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009551873A Pending JP2010520223A (ja) 2007-03-02 2008-02-29 発作関連障害のための組成物および方法

Country Status (5)

Country Link
EP (1) EP2131839A2 (de)
JP (1) JP2010520223A (de)
AU (1) AU2008223066A1 (de)
CA (1) CA2679917A1 (de)
WO (1) WO2008109437A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1430033A4 (de) 2001-08-31 2004-12-15 Univ Northwestern Entzündunshemmende und proteinkinaseinhibierende zusammensetzung und deren verwendung
ATE523199T1 (de) 2004-11-02 2011-09-15 Univ Northwestern Pyridazinverbindungen und verfahren
EP1812408B1 (de) 2004-11-02 2013-10-09 Northwestern University Pyridazinverbindungen, zusammensetzungen und verfahren
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
CA2650625A1 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
JP2012507540A (ja) * 2008-10-30 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション ピリダジンカルボキサミド・オレキシン受容体アンタゴニスト
BRPI0919876A8 (pt) 2008-10-30 2016-02-10 Merck Sharp & Dohme Composto, composição farmacêutica, uso de um composto, e, método para intensificar a qualidade do sono, para tratar insônia, e para tratar ou controlar obesidade em um paciente mamífero que necessita do mesmo.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073472A1 (en) * 2001-08-31 2006-04-06 Watterson D M Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2511366A1 (fr) * 1981-08-11 1983-02-18 Sanofi Sa Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
DE3217325A1 (de) * 1982-05-08 1983-11-10 Hoechst Ag, 6230 Frankfurt 3-amino-6-aryl-1,2,4-triazolo(4,3-b)-pyridazine, ihre herstellung und ihre verwendung
US4654343A (en) * 1985-10-31 1987-03-31 American Cyanamid Company N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas
CA2650704A1 (en) * 2006-04-28 2007-11-08 Northwestern University Salts of pyridazine compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073472A1 (en) * 2001-08-31 2006-04-06 Watterson D M Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013017933; ＨＵ，　Ｗ．　ｅｔ　ａｌ: 'Ｄｅｖｅｌｏｐｍｅｎｔ　ｏｆ　ａ　ｎｏｖｅｌ　ｔｈｅｒａｐｅｕｔｉｃ　ｓｕｐｐｒｅｓｓｏｒ　ｏｆ　ｂｒａｉｎ　ｐｒｏｉｎｆｌａｍｍａｔｏｒｙ　ｃｙｔｏｋｉｎｅ　ｕｐ-ｒｅｇｕｌａｔｉｏｎ　ｔｈａｔ　ａ' ＢＩＯＯＲＧＡＮＩＣ　＆　ＭＥＤＩＣＩＮＡＬ　ＣＨＥＭＩＳＴＲＹ　ＬＥＴＴＥＲＳ Ｖｏｌ．１７，　ｎｏ．２, 200701, ｐ．４１４-４１８ *
JPN7013001427; ＶＥＺＺＡＮＩ，　Ａ．　ｅｔ　ａｌ: 'Ｂｒａｉｎ　Ｉｎｆｌａｍｍａｔｉｏｎ　ａｎｄ　Ｓｅｉｚｕｒｅｓ' ＥＰＩＬＥＰＳＹ　ＣＵＲＲＥＮＴＳ Ｖｏｌ．４，　Ｎｏ．２, 2004, ｐ．７３-７５ *
JPN7013001428; ＶＥＺＺＡＮＩ，　Ａ．　ｅｔ　ａｌ: 'Ｆｕｎｃｔｉｏｎａｌ　ｒｏｌｅ　ｏｆ　ｉｎｆｌａｍｍａｔｏｒｙ　ｃｙｔｏｋｉｎｅｓ　ａｎｄ　ａｎｔｉｉｎｆｌａｍｍａｔｏｒｙ　ｍｏｌｅｃｕｌｅｓ　ｉｎ　ｓｅｉｚｕｒｅｓ　ａｎｄ　ｅｐｉｌｅｐｔｏｇｅｎ' ＥＰＩＬＥＰＳＩＡ Ｖｏｌ．４３　Ｓｕｐｐｌ．５, 2002, ｐ．３０-３５ *
JPN7013001429; ＶＥＺＺＡＮＩ，　Ａ．　ｅｔ　ａｌ: 'Ｂｒａｉｎ　ｉｎｆｌａｍｍａｔｉｏｎ　ｉｎ　ｅｐｉｌｅｐｓｙ：　ｅｘｐｅｒｉｍｅｎｔａｌ　ａｎｄ　ｃｌｉｎｉｃａｌ　ｅｖｉｄｅｎｃｅ．' ＥＰＩＬＥＰＳＩＡ Ｖｏｌ．４６，　Ｎｏ．１１, 2005, ｐ．１７２４-１７４３ *

Also Published As

Publication number Publication date
AU2008223066A1 (en) 2008-09-12
CA2679917A1 (en) 2008-09-12
WO2008109437A3 (en) 2009-11-19
EP2131839A2 (de) 2009-12-16
WO2008109437A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
US8158627B2 (en) Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
JP2010520223A (ja) 発作関連障害のための組成物および方法
US9408845B2 (en) Formulations containing pyridazine compounds
ES2800026T3 (es) Tratamiento de enfermedades inmunitarias e inflamatorias
US20100168120A1 (en) Salts of pyridazine compounds
ES2687598T3 (es) Moduladores del canal de sodio para el tratamiento del dolor y la diabetes
JP2010510254A (ja) アルツハイマー病および関連の神経変性疾患のための併用処置
WO2007127475A2 (en) Pyridazines for demyelinating diseases and neuropathic pain
WO2007130383A2 (en) Compositions and treatments using pyridazine compounds and secretases
EP3046559A1 (de) Behandlung von durch abnormale lymphozytenfunktion verursachten krankheiten mit einem hdac6-inhibitor
US20070244071A1 (en) Treatment of proliferative diseases
US20210163406A1 (en) Bumetanide Derivatives for the Therapy of Stroke and Other Neurological Diseases/Disorders Involving NKCCs
US20100210590A1 (en) Compositions and treatments for seizure-related disorders
JP2008518955A (ja) ピリダジン化合物および方法
CA2944069A1 (en) Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof
WO2020247756A1 (en) Small molecules to relax uterine smooth muscle contractions
CN113677345A (zh) 用于治疗孤独症谱系障碍的氨基甲酰基环己烷衍生物
JP2022078194A (ja) 胚着床を促進し、流産を防ぐためのオキシトシンアンタゴニスト投与レジメン
EP2732815A1 (de) Modulatoren der intrazellulären Chloridkonzentration zur Behandlung des Fragilen X-Syndroms
WO2019178166A1 (en) Amphiphilic thiol compounds and uses thereof
JP2024509265A (ja) 赤血球増加症を処置するための組成物および方法
WO2016206097A1 (zh) 新的5型磷酸二酯酶抑制剂及其应用
KR20110083324A (ko) 비타민 ｃ를 포함하는 태아의 신경세포 보호용 조성물

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110218

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131002